The Effects of the COVID Pandemic on Patients with IBD: Lessons Learned and Future Directions.
Eva ZhangBritt ChristensenFinlay Alistair MacraeRupert W L LeongPublished in: Journal of clinical medicine (2022)
The COVID-19 pandemic has caused extended global disruption and changed healthcare behaviour and delivery in patients with inflammatory bowel disease, many of whom take immune modifying treatment. Although there were fears about the vulnerability of IBD patients to SARS-CoV-2 infection, we have learnt that overall IBD patients are equivalent to the general population in both viral acquisition and infection outcomes. Overall IBD patients obtain effective vaccine-induced immune responses, although in some groups an additional vaccine dose is required to constitute a primary course. The pandemic has led to significant changes in healthcare delivery, some of which will be enduring. As we grapple with the challenges of recovery, the lessons learnt will continue to be important in optimising outcomes in future outbreaks.
Keyphrases
- healthcare
- end stage renal disease
- ejection fraction
- newly diagnosed
- immune response
- prognostic factors
- sars cov
- peritoneal dialysis
- type diabetes
- coronavirus disease
- dendritic cells
- oxidative stress
- skeletal muscle
- patients with inflammatory bowel disease
- combination therapy
- inflammatory response
- high glucose
- replacement therapy